Scientists researching Alzheimer’s disease have identified a previously overlooked enzyme that may play a major role in driving the progression of the world’s most common form of dementia — and they have already found a way to block it in laboratory models.
The enzyme, known as IDOL, was not previously considered a major factor in Alzheimer’s pathology. However, new research published in May 2026 suggests the enzyme may actively accelerate the disease by interfering with the brain’s natural ability to clear toxic proteins linked to neurodegeneration.
Researchers found that IDOL appears to disrupt the removal of amyloid plaques and tau tangles, the two hallmark protein abnormalities strongly associated with Alzheimer’s disease. These toxic buildups damage brain cells over time, eventually leading to memory loss, confusion, impaired reasoning and the progressive loss of independent functioning.
By shutting down IDOL activity in laboratory models, scientists were able to significantly reduce the accumulation of these harmful proteins. The findings immediately attracted attention across the neuroscience community, with several independent researchers describing the discovery as one of the most promising new therapeutic targets identified in recent years.
Unlike many previous Alzheimer’s treatments that attempted to remove plaques after they had already formed, targeting IDOL could potentially interfere much earlier in the disease process by restoring the brain’s own protein-clearing mechanisms.
Scientists say this distinction is critical.
For decades, Alzheimer’s research has struggled with repeated clinical trial failures despite billions of dollars in investment. Many experimental drugs succeeded in reducing amyloid levels but failed to produce meaningful improvements in cognition or disease progression once tested in patients.
The IDOL discovery introduces a different strategy — preventing the toxic buildup process itself from spiralling out of control.
The findings arrive at a time when global concern surrounding dementia is rapidly intensifying. Alzheimer’s disease currently affects an estimated 55 million people worldwide, with projections suggesting that number could nearly triple to 139 million by 2050 as populations continue ageing.
The financial impact is equally staggering. Combined healthcare costs, caregiving burdens and lost productivity associated with dementia already exceed one trillion dollars annually worldwide.
Researchers emphasise that the new findings do not represent a cure for Alzheimer’s disease. Human clinical trials will still be required to determine whether blocking IDOL can safely slow or prevent cognitive decline in patients.
However, scientists believe the discovery provides one of the clearest new biological targets to emerge in Alzheimer’s research in recent years.
The announcement also coincides with another major dementia study released by the University of California San Diego, which analysed health data from more than 17,000 adults. Researchers found that women may be significantly more vulnerable than men to common dementia risk factors — a finding that may help explain why women develop Alzheimer’s disease at nearly twice the rate of men globally.
The UC San Diego researchers argued that future prevention strategies may need to be specifically tailored for women rather than relying on broad universal approaches.
Together, both studies add to a growing wave of Alzheimer’s research emerging throughout 2025 and 2026 that suggests scientists may finally be moving closer to understanding the disease’s core biological mechanisms.
While enormous challenges remain, the identification of IDOL as a key driver of neurodegeneration opens an entirely new front in the battle against dementia — one that researchers say deserves urgent global attention.
